MedPath

Tagged News

Landmark TAILORx Trial Shows 70% of Early-Stage Breast Cancer Patients Can Safely Skip Chemotherapy

Precision MedicineOncology
• The TAILORx trial, involving over 10,000 women, demonstrates that approximately 70% of patients with hormone-receptor positive, HER2-negative early breast cancer can safely avoid chemotherapy when guided by genetic testing. • Women over 50 with Oncotype DX recurrence scores of 0-25 showed no significant survival benefit from adding chemotherapy to hormone therapy alone. • The findings could spare an estimated 65,000 women annually in the US from chemotherapy's toxic side effects while maintaining excellent long-term outcomes. • This precision medicine approach represents the largest breast cancer trial to date and marks a paradigm shift toward personalized treatment strategies.

Novartis's Kymriah: Breakthrough CAR-T Therapy Priced at $475,000 Sparks Value Debate

CAR-TDrug ApprovalOncology
  • Novartis's Kymriah, the first FDA-approved CAR-T cell therapy for pediatric acute lymphoblastic leukemia, demonstrates an impressive 83% remission rate in patients who failed traditional treatments.
  • The therapy's $475,000 price tag has ignited debate among healthcare experts, with some defending it as comparable to bone marrow transplants while others argue it's excessive despite its breakthrough status.
  • Novartis has implemented innovative value-based pricing models, including outcome-based contracts where payment is contingent upon patient response and indication-specific pricing for future approvals.

D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial

OncologyPrecision MedicineTargeted Therapy
  • A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.
  • The novel compound from D3Bio inhibits KRAS-G12C mutations at a faster rate and potentially longer duration than existing treatments, according to Dr. Herbert Loong from CUHK's Department of Clinical Oncology.
  • Researchers are planning phase 3 trials with the goal of positioning D3S-001 as a first-line treatment option for patients with KRAS-G12C-driven cancers of the lung, pancreas, and colon.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.